SBIR & Research
SBIR Commercialization Plan: What Each Agency Requires
Grant Writing Service Editorial Team
June 12, 2026 · 5 min read
Table of contents
Key takeaways
- Every SBIR agency scores commercialization, but the format ranges from a section inside the technical narrative to a stand-alone 12-page NIH Phase II plan.
- At Phase I, most agencies want the customer, market, competition, and business model in one to a few pages; DOE requires a separate two-page plan and declines applications without it.
- Reviewers believe specifics: a named buyer, a bottom-up market estimate, honest competitors, and evidence such as letters of intent.
An SBIR commercialization plan is the part of a Small Business Innovation Research proposal that shows how the funded technology will reach a paying customer or government user: the target customer, the market, the competition, the intellectual property position, the revenue model, and the financing needed after the award. Every participating agency scores it, but what it looks like depends on the agency and the phase. At Phase I it is often a section of the technical narrative; at NIH Phase II it is a stand-alone document of up to 12 pages.
What each agency asks for
SBIR.gov's tutorial on Phase I commercialization summarizes the five largest agencies. Combined with the NIH and DOE application guidance, the requirements look like this:
| Agency | Phase I | Phase II |
|---|---|---|
| NIH and HHS | No separate plan. Commercial potential is argued in the Significance part of the Research Strategy | A Commercialization Plan of up to 12 pages, also required for Fast-Track and Direct to Phase II |
| NSF | A commercial opportunity discussion inside the project description; SBIR.gov notes a recommended two to four pages covering the societal need, market, how the opportunity was validated, customers, and business model | A fuller commercialization plan; Commercial Impact is one of NSF's three review criteria at every phase |
| DoD | A commercialization strategy of about one page in the technical volume, covering market need, market size, and a schedule of expected results across DoD, other agencies, and private markets | More detailed transition and commercialization content, with components adding their own rules |
| DOE | A mandatory two-page Phase I Commercialization Plan covering market opportunity, intellectual property, company and team, and revenue; applications without it are declined without review | A more detailed plan per the funding opportunity |
| NASA | A "potential post applications" section identifying NASA, other government, and commercial uses, likely customers, and an initial strategy | Infusion into NASA programs plus commercial markets |
Always work from the current solicitation, because formats change between cycles. The programs were reauthorized in April 2026 with an added emphasis on measurable results, and agencies are still issuing updated solicitations under the new law.
The NIH Phase II plan, section by section
NIH's application guide asks for a document titled "Commercialization Plan," no longer than 12 pages. The National Institute on Drug Abuse's guide for applicants organizes it into these parts:
- Value of the project, expected outcomes, and impact: the product, the problem it solves, and its advantages over current options, including non-commercial benefits.
- Company overview: history, size, core competencies, prior federal and private funding, products with sales, and how the company will grow from a research business into a commercial one.
- Market, customer, and competition: market size and segments, the end user and the people who make the purchase decision, and current and potential competitors.
- Intellectual property protection: patents held or licensed, filing strategy, and who owns what.
- Regulatory strategy: the path to clearance or approval and how data security will be handled.
- Finance plan: how much money each later stage needs, from which sources, and when, supported where possible by letters of commitment or intent.
- Production and marketing plan: how the product will be made and sold.
- Revenue stream: how the company will earn money from the product.
- Risk analysis and mitigation.
The guide's most useful reminder is that reviewers read the commercialization plan early and that few review panelists are business experts, so a clear value proposition matters more than jargon.
Writing the sections reviewers test hardest
The customer
Name who pays. "The healthcare market" is not a customer; "the nurse manager and value-analysis committee at a mid-size hospital, who approve monitoring equipment purchases" is. Distinguish the end user from the economic buyer and anyone else who can block the sale, because in health care and defense they are rarely the same person. For DoD, name the program office or end user and the acquisition path. Specificity is evidence that you have talked to real buyers.
Market size
Build the estimate from the bottom up: number of buyers times realistic price times plausible adoption, then show where it sits within the total, served, and target markets. Cite the sources behind each input. A sourced, narrow number persuades; a billion-dollar total with no path to your share does not. The NIDA guide specifically warns that overestimating market penetration is a common mistake, especially in mature, slow-growing markets.
Competition
List the real alternatives, including the status quo of doing nothing, and state your durable advantage: performance, cost, workflow fit, regulatory position, or protected intellectual property. "No competitors" reads as an applicant who has not looked.
Intellectual property
State what is filed, issued, licensed, or held as trade secrets, accurately. DOE's guidance is blunt: do not claim a filing you have not made or "patent pending" status without an application number. Address freedom to operate if another party's patents are near your space. If your technology came from a university, describe the license or option.
Revenue model
Explain how money reaches the company: product sales, licensing, subscription, services, or government contracts. Tie the pricing logic to the customer you named, at a level of detail suited to the phase. A Phase I plan needs a credible model; a Phase II plan needs numbers.
Financing after the award
SBIR pays for research and development, not for launching a product. Show how you will bridge from the award to revenue: a Phase II, private investment, strategic partners, or non-SBIR government contracts in Phase III. Letters of commitment or intent from investors or partners are the strongest evidence you can include. Investors and lenders on that roadmap will usually ask for a full investor-ready business plan with multi-year projections, so build it from the same market figures the commercialization plan uses.
How much to write at each phase
At Phase I, feasibility is the main question and the commercial case supports it. Reviewers want a credible customer, a sensible market estimate, and evidence of early validation such as customer interviews or letters of interest. At Phase II, the agency is deciding whether to put much larger money behind getting the product out, so the plan has to show the team, financing, regulatory path, and revenue in real detail. Our comparison of Phase I and Phase II goals shows where the emphasis shifts.
The commercialization content should agree with the technical narrative. If the one-page Specific Aims promises a device for hospital wards, the plan should be about hospital buyers, not home care. For how the plan fits the full application and each agency's format, see how to write an SBIR proposal, and for realistic planning around the odds of funding, see the SBIR success rate by agency.
If you would rather hand the business case to a team that writes these alongside the science, our SBIR and STTR grant writing service prepares commercialization plans for every phase.
